Patents Assigned to ICOS
  • Monoclonal antibodies specific for integrin &agr;-d subunit
    Patent number: 6620915
    Abstract: The present invention relates to monoclonal antibodies immunospecific for &agr;d integrin, and antibodies that compete with said antibodies for &agr;d binding.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: September 16, 2003
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Treatment of female arousal disorder
    Patent number: 6613768
    Abstract: A method of treating female arousal disorder (FAD) in a female patient is disclosed. The method includes orally administering an agent that inhibits cyclic guanosine 3′5′-monophosphate specific phosphodiesterase type 5 to the female patient.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: September 2, 2003
    Assignee: Lilly ICOS LLC
    Inventors: Lora L. Allemeier, Diane L. Brashear, Kenneth M. Ferguson, William E. Pullman
  • Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction
    Patent number: 6608065
    Abstract: The use of (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2′,1′:6,1]pyrido[3,4-b]indole -1,4-dione, (3S, 6R, 12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyphenyl)pyrazino[2′, 1′:6,1]pyrido[3,4-b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in the treatment of impotence.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: August 19, 2003
    Assignee: ICOS Corporation
    Inventor: Alain Claude-Marie Daugan
  • Phosphodiesterase 10
    Publication number: 20030148378
    Abstract: The present invention provides novel human PDE10 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE10 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE10 polypeptides. The invention further provides methods to identify binding partners of PDE10, and more particularly, binding partners that modulate PDE10 enzyme activity.
    Type: Application
    Filed: December 20, 2001
    Publication date: August 7, 2003
    Applicant: ICOS Corporation
    Inventor: Kate Loughney
  • Daily treatment for erectile dysfunction using a PDE5 inhibitor
    Publication number: 20030144296
    Abstract: The present invention relates to phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 10 mg unit dosage are useful for the treatment of sexual dysfunction by daily administration of the PDE5 inhibitor. The articles of manufacture described herein are characterized by PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, especially erectile dysfunction, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes and with an improvement of vascular conditioning.
    Type: Application
    Filed: January 14, 2003
    Publication date: July 31, 2003
    Applicant: Lilly ICOS LLC
    Inventors: John S. Whitaker, Inigo Saenz de Tejada, Kenneth M. Ferguson
  • Human poly (ADP-ribose) polymerase 2 materials and methods
    Patent number: 6599727
    Abstract: The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: July 29, 2003
    Assignee: ICOS Corporation
    Inventors: Erik Christenson, Anthony J. Demaggio, Phyllis S. Goldman, David L. McElligott
  • Articles of manufacture
    Publication number: 20030100478
    Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction. The articles of manufacture described herein are characterized by selective PDE5 inhibition, and accordingly, provide a benefit in therapeutic areas where inhibition of PDE5 is desired, with minimization or elimination of adverse side effects resulting from inhibition of other phosphodiesterase enzymes.
    Type: Application
    Filed: July 19, 2002
    Publication date: May 29, 2003
    Applicant: Lilly ICOS LLC
    Inventors: Jeffrey T. Emmick, Kenneth M. Ferguson, William E. Pullman, John S. Whitaker
  • Phosphodiesterase 8A
    Patent number: 6566087
    Abstract: The present invention provides novel human PDE8 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE8 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE8 polypeptides.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: May 20, 2003
    Assignee: ICOS Corporation
    Inventor: Kate Loughney
  • Novel human beta2 integrin alpha subunit
    Publication number: 20030077278
    Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.
    Type: Application
    Filed: June 26, 2001
    Publication date: April 24, 2003
    Applicant: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Platelet-activating factor acetylhydrolase
    Publication number: 20030072747
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.
    Type: Application
    Filed: October 13, 2001
    Publication date: April 17, 2003
    Applicant: ICOS Corporation
    Inventors: Lawrence S. Cousens, Christine D. Eberhardt, Patrick Gray, Hai Le Trong, Larry W. Tjoelker, Cheryl L. Wilder
  • ICAM-4 materials and methods
    Publication number: 20030068659
    Abstract: Methods for quantitating concentration of circulating ICAM-4 in association with various neurodegenerative disorders are provided.
    Type: Application
    Filed: December 18, 2001
    Publication date: April 10, 2003
    Applicant: ICOS Corporation
    Inventors: Patrick D. Kilgannon, W. Michael Gallatin
  • Cyclic GMP-binding, cyclic GMP-specific phosphodiesterase materials and methods
    Publication number: 20030054992
    Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.
    Type: Application
    Filed: April 3, 2002
    Publication date: March 20, 2003
    Applicant: ICOS Corporation
    Inventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
  • Phosphodiesterase 10
    Publication number: 20030044950
    Abstract: The present invention provides novel human PDE10 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE10 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE10 polypeptides. The invention further provides methods to identify binding partners of PDE 10, and more particularly, binding partners that modulate PDE10 enzyme activity.
    Type: Application
    Filed: February 26, 2002
    Publication date: March 6, 2003
    Applicant: ICOS Corporation
    Inventor: Kate Loughney
  • Cytoplasmic modulators of integrin regulation/signaling
    Publication number: 20030044958
    Abstract: The present invention provides purified and isolated polynucleotides encoding IRP polypeptides which regulate &bgr;2 and &bgr;7 integrins and which are contemplated to participate in integrin signaling and/or recycling pathways. Also provided are methods for identifying modulators of IRP activities and methods for identifying other proteins which interact with IRP polypeptides in signaling pathways. Modulators of IRP interactions are contemplated to be useful, for example, in monitoring and treating inflammatory processes involving leukocytes.
    Type: Application
    Filed: March 26, 2001
    Publication date: March 6, 2003
    Applicant: ICOS Corporation
    Inventors: Donald E. Staunton, Brian P. Lispky
  • Inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 6518277
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&dgr;) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K&dgr; plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K&dgr;, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K&dgr; activity, including compounds that selectively inhibit PI3K&dgr; activity. Methods of using PI3K&dgr; inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K&dgr; inhibitory compounds to inhibit PI3K&dgr;-mediated processes in vitro and in vivo.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: February 11, 2003
    Assignee: ICOS Corporation
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
  • ATR-2 cell cycle checkpoint
    Publication number: 20030023055
    Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.
    Type: Application
    Filed: September 21, 2001
    Publication date: January 30, 2003
    Applicant: ICOS Corporation
    Inventors: Kate Loughney, Kathleen S. Keegan
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20030013754
    Abstract: Pyrrole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: January 22, 2002
    Publication date: January 16, 2003
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Amy Oliver, Carmen C. Hertel
  • Novel CREBa isoform
    Publication number: 20020197712
    Abstract: The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.
    Type: Application
    Filed: June 19, 2001
    Publication date: December 26, 2002
    Applicant: ICOS Corporation
    Inventor: Kathleen S. Keegan
  • Methods of identifying agents that modulate the binding between MDC and an MDC receptor
    Patent number: 6498015
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: December 24, 2002
    Assignee: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray, Carol J. Raport
  • Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
    Patent number: 6486186
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: November 26, 2002
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo